United Therapeutics 8-K 2012
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
Pursuant to Section 13 or 15 (d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 1, 2012
United Therapeutics Corporation
(Exact Name of Registrant as Specified in Charter)
Registrants telephone number, including area code: (301) 608-9292
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
2011 Executive Officer Salaries and Bonus Opportunities
On February 1, 2012, the Compensation Committee (the Committee) of the Board of Directors (the Board) of United Therapeutics Corporation (the Company) approved the 2012 salaries and cash and long-term incentive bonus target opportunities for the Companys executive officers as follows.
· Dr. Martine Rothblatts annual base salary is increased from $936,000 to $964,080. Dr. Rothblatts annual cash incentive bonus target opportunity is 100% of her base salary. Dr. Rothblatt may be entitled to receive a stock option grant on December 31, 2012, in accordance with the formula set forth in her employment agreement, which takes into account the rise, if any, in the Companys market capitalization from December 2011 to December 2012.
· Dr. Roger Jeffs annual base salary is increased from $759,200 to $782,000. Dr. Jeffs annual cash incentive bonus target opportunity for 2012 is 75% of his base salary, and his annual long-term incentive bonus target opportunity remains unchanged at 175,000 Share Tracking Awards (STAP >Awards) under the Companys 2011 Share Tracking Awards Plan (the 2011 Plan).
· Mr. Paul Mahons annual base salary is increased from $660,400 to $680,200. Mr. Mahons annual cash incentive bonus target opportunity is 60% of his base salary, and his annual long-term incentive bonus target opportunity remains unchanged at 125,000 STAP Awards under the 2011 Plan.
· Mr. John Ferraris annual base salary is increased from $457,600 to $526,240. Mr. Ferraris annual cash incentive bonus target opportunity is 60% of his base salary, and his annual long-term incentive bonus target opportunity remains unchanged at 125,000 STAP Awards under the 2011 Plan.
The foregoing 2012 contingent cash incentive bonus target opportunities will be assessed pursuant to the Company-Wide Milestone Incentive Bonus Program criteria applicable for 2012. In addition, the Committee may exercise its discretion to increase the award percentage earned.
When assessing the foregoing 2012 long-term incentive bonus target opportunities for Dr. Jeffs and Messrs. Mahon and Ferrari, the Committee will consider the following factors: (i) a subjective evaluation of individual performance, including contribution to the advancement of corporate objectives, impact on financial results and strategic accomplishments; (ii) the Companys overall performance, financial condition and prospects; and (iii) accomplishments under the Company-Wide Milestone Incentive Bonus Program.
A detailed discussion of the Companys executive compensation program will be provided in its definitive proxy statement in connection with its 2012 annual meeting of shareholders, which the Company expects to file with the Securities and Exchange Commission on or about April 30, 2012.
Amendments to Share Tracking Awards Plans
Also on February 1, 2012, the Board, acting upon the recommendation of the Committee, approved amendments to both the 2011 Plan and the United Therapeutics Corporation Share Tracking Awards Plan adopted in 2008 (the 2008 Plan). The amendment to the 2008 Plan provides that no future STAP Awards will be issued under the 2008 Plan and that any outstanding STAP Awards previously granted under the 2008 Plan that are forfeited, canceled or expired will effectively be canceled and unavailable for future grant under the 2008 Plan. The amendment to the 2011 Plan increases the maximum number of STAP Awards authorized for grant thereunder by 2,000,000 awards. This increase is intended to accommodate anticipated grants of STAP Awards under our long-term incentive bonus and compensation programs during 2012.
As of February 1, 2012, before the adoption of the amendments described above, there were approximately 418,000 STAP Awards available for issuance under the 2008 Plan, and 400,000 STAP Awards available for issuance under the 2011 Plan. As a result of the amendments, the 418,000 available STAP Awards under the 2008 Plan were effectively cancelled. Following adoption of the amendments, there are approximately 2,400,000 STAP Awards available for issuance as of February 1, 2012.
The 2008 Plan was originally filed on July 31, 2008, as Exhibit 10.1 to the Companys Quarterly Report on Form 10-Q. The 2011 Plan was originally filed on March 18, 2011, as Exhibit 10.1 to the Companys Current Report on Form 8-K. The text of the amendments to each of the 2008 Plan and the 2011 Plan are filed herewith as Exhibits 10.1 and 10.2, respectively.
Item 8.01 Other Events
On February 6, 2012, United Therapeutics issued the press release attached hereto as Exhibit 99.1, which is incorporated herein by reference.
Item 9.01 Exhibits
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.